Post-treatment gametocyte carriage — DTM&H MCQ

Correct answer: C — Single low-dose primaquine

Single low-dose primaquine (option B) is correct because it is the recommended gametocytocidal agent added to standard falciparum treatment when the aim is to reduce onward transmission, and this patient has no contraindication (G6PD deficiency excluded). Persistent gametocytaemia after adequate blood-stage treatment does not represent treatment failure, since gametocytes are relatively insensitive to most schizontocidal drugs and can persist for days to weeks after asexual parasite clearance. A single low dose of primaquine (0.25 mg base/kg) shortens the duration of gametocyte carriage and infectivity to mosquitoes without needing prior G6PD testing, as the low dose carries minimal haemolytic risk even in deficient individuals, and is fully safe here as deficiency has already been excluded. This fits UK guidance on managing imported falciparum malaria where transmission-reduction is a stated local policy goal. Why the other options are wrong: A. Doxycycline extension: doxycycline has no useful gametocytocidal activity and extending a schizontocidal antibiotic does nothing to address persistent gametocytes or transmission risk. D. No antimalarial change: this ignores the explicit local policy to reduce transmission; gametocytes, while not indicating clinical relapse, still pose an onward transmission risk that primaquine specifically addresses. E. Repeat chloroquine course: falciparum malaria is treated with ACT or quinine-based regimens, not chloroquine, due to widespread chloroquine resistance, and chloroquine has negligible effect on mature gametocytes. B. Ivermectin mass dosing: ivermectin targets mosquito vectors indirectly by killing insects that bite treated humans, it is not a validated individual patient gametocytocidal antimalarial and mass dosing is a vector-control strategy, not a treatment for an individual case. Key point: In afebrile, G6PD-normal patients with persistent falciparum gametocytaemia, add single low-dose primaquine specifically to reduce transmission, as it does not treat blood-stage disease but clears gametocytes.

Reference: Lalloo DG et al, UK malaria treatment guidelines 2016, Journal of Infection (PHE/UKHSA endorsed); https://pmc.ncbi.nlm.nih.gov/articles/PMC7132403/